Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
FDA Calls for Study on Aldeyra’s Reproxalap in DED
Aldeyra Therapeutics announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for reproxalap, an investigational drug candidate designed for the treatment of dry eye disease.…
Reviving Hope for Amblyopia: Late-Stage Treatment
In children with amblyopia, often referred to as “lazy eye,” one eye exhibits weaker vision than the other due to various factors. This weaker eye may struggle with focusing, misalignment due to strabismus, or vision obstruction from conditions like cataracts…
UCL-Moorfields Eye Hospital Secures £5M for Research Center
The Sir Jules Thorn Charitable Trust has allocated £5 million towards the establishment of a research center within Oriel, the collaborative initiative between UCL and Moorfields Eye Hospital aimed at advancing eye health. Partnering with Moorfields Eye Charity and Moorfields…
Negative Effect of Atropine Drops After Glaucoma Surgery
According to a report by an international team of researchers, atropine instillation after trabeculectomy should be discouraged since it causes greater and longer lasting reduction in visual quality.1 The study’s lead author is Panagiotis Laspas, MD, of the Department of…
Perfluorohexyloctane Drops Help Alleviate Dry Eye
According to recent research, perfluorohexyloctane eye drops (SHR8058) demonstrated significant improvement in both the signs and symptoms of dry eye disease (DED) linked to meibomian gland dysfunction (MGD) with rapid effectiveness in Chinese patients. The findings showed that the perfluorohexyloctane…
4DMT Reports Positive Interim Data for Wet AMD Treatment
4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…
Kiora, Théa Partner for Retinal Disease Treatment
Kiora Pharmaceuticals has joined forces with Théa Open Innovation (TOI), a sister company of Laboratoires Théa, to develop and commercialize KIO-301 for the treatment of degenerative retinal diseases. The strategic agreement grants Théa exclusive worldwide development and commercialization rights, excluding…
FDA Approves Modified Axpaxli Trial by Ocular Therapeutix
Ocular Therapeutix announced that the FDA has granted approval for a modification to the special protocol assessment (SPA) agreement for the pivotal phase 3 SOL clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI). This modification marks a…
FDA Approval and Funding for ONS-5010
In a significant stride towards advancing its clinical development program for ONS-5010, Outlook Therapeutics has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol. This trial aims to evaluate the…
Aviceda Launches Phase 2 Clinical Trial for AVD-104
Aviceda Therapeutics announced a significant milestone in the development of its lead ophthalmic candidate, AVD-104, with the enrollment of the first patient in the GLYCO phase 2 US clinical trial. The trial aims to evaluate the efficacy and safety of…